Cite

HARVARD Citation

    Morschhauser, F. et al. (2019). Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet. 6 (8), pp. e429-e437. [Online]. 
  
Back to record